Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Hematopoietic Stem Cell Transplantation/methods"'
Autor:
Urs Schanz, Claire Seydoux, Nathan Cantoni, Patrick Simon, Stavroula Masouridi Levrat, Sabine Gerull, Joerg Halter, Michael Medinger, Yves Chalandon, Gayathri Nair, Dominik Heim, Marc Ansari, Jakob Passweg
Publikováno v:
Annals of Hematology
Annals of hematology, Vol. 100, No 1 (2021) pp. 209-216
Annals of hematology, Vol. 100, No 1 (2021) pp. 209-216
Busulfan and cyclophosphamide (BuCy) is a frequently used myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation (allo-HCT). Theoretical considerations and pharmacological data indicate that application of busulfan prior
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46778682dca6af300f13a48b5a897ccf
http://europepmc.org/articles/PMC7782401
http://europepmc.org/articles/PMC7782401
Autor:
Grzegorz W. Basak, Boris V. Afanasyev, Péter Reményi, Noel Milpied, Paolo Corradini, Madan Jagasia, Olaf Penack, Henrik Sengeloev, Frank Kroschinsky, Zinaida Peric, Ibrahim Yakoub-Agha, Rafael F. Duarte, Dietger Niederwieser, Edward Kanfer, Steffie van der Werf, Fabio Ciceri, Alessandro Rambaldi, Didier Blaise, Patrice Chevallier, Carlos Solano, Hildegard Greinix, Eric Beohou, Luca Castagna, Nicolaus Kröger, Hélène Schoemans, Agnieszka Tomaszewska, Christian Koenecke, Jean Bourhis, Benedetto Bruno, Christof Scheid, Marco Ladetto, Gérard Socié
Publikováno v:
Frontiers in Immunology
Tomaszewska, A, Jagasia, M, Beohou, E, van der Werf, S, Blaise, D, Kanfer, E, Milpied, N, Reményi, P, Ciceri, F, Bourhis, J H, Chevallier, P, Solano, C, Socié, G, Bruno, B, Rambaldi, A, Castagna, L, Kröger, N, Corradini, P, Afanasyev, B, Ladetto, M, Niederwieser, D, Scheid, C, Sengeloev, H, Kroschinsky, F, Yakoub-Agha, I, Schoemans, H, Koenecke, C, Penack, O, Perić, Z, Greinix, H, Duarte, R F & Basak, G W 2021, ' Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes : EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies ', Frontiers in Immunology, vol. 11, 613954 . https://doi.org/10.3389/fimmu.2020.613954
Frontiers in Immunology, Vol 11 (2021)
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Tomaszewska, A, Jagasia, M, Beohou, E, van der Werf, S, Blaise, D, Kanfer, E, Milpied, N, Reményi, P, Ciceri, F, Bourhis, J H, Chevallier, P, Solano, C, Socié, G, Bruno, B, Rambaldi, A, Castagna, L, Kröger, N, Corradini, P, Afanasyev, B, Ladetto, M, Niederwieser, D, Scheid, C, Sengeloev, H, Kroschinsky, F, Yakoub-Agha, I, Schoemans, H, Koenecke, C, Penack, O, Perić, Z, Greinix, H, Duarte, R F & Basak, G W 2021, ' Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes : EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies ', Frontiers in Immunology, vol. 11, 613954 . https://doi.org/10.3389/fimmu.2020.613954
Frontiers in Immunology, Vol 11 (2021)
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Rituximab (R) is increasingly incorporated in reduced intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (alloHCT) in patients with B-cell malignancies, not only to improve disease control, but also to prevent gra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f4d09c87c618906776d7cfa22d15fc6
http://europepmc.org/articles/PMC7884746
http://europepmc.org/articles/PMC7884746
Autor:
Markus Munder, Hartmut Goldschmidt, Hans Salwender, Marc S. Raab, Jana Schlenzka, Martin Goerner, Marc-Andrea Baertsch, Martin Hoffmann, Peter Brossart, Dirk Hose, Anna Jauch, Jan Dürig, Stephan Fuhrmann, Steffen Luntz, Christina Kunz, Jens Hillengaß, Hans-Walter Lindemann, Kai Neben, Elias K. Mai, Henk M. Lokhorst, Thomas Hielscher, Ulrich Dührsen, Igor Wolfgang Blau, Hans Martin, Mathias Hänel, Pieter Sonneveld, Christof Scheid, Katja Weisel, Uta Bertsch, Helga Bernhard, Anja Seckinger, Britta Besemer
Publikováno v:
Blood Cancer Journal
German-Speaking Myeloma Multicenter Group (GMMG) 2021, ' Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma ', Blood cancer journal, vol. 11, no. 1, 1 . https://doi.org/10.1038/s41408-020-00390-3
Blood Cancer Journal, 11(1):1. Nature Publishing Group
Blood cancer journal, 11(1):1. Nature Publishing Group
Blood Cancer Journal, Vol 11, Iss 1, Pp 1-10 (2021)
German-Speaking Myeloma Multicenter Group (GMMG) 2021, ' Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma ', Blood cancer journal, vol. 11, no. 1, 1 . https://doi.org/10.1038/s41408-020-00390-3
Blood Cancer Journal, 11(1):1. Nature Publishing Group
Blood cancer journal, 11(1):1. Nature Publishing Group
Blood Cancer Journal, Vol 11, Iss 1, Pp 1-10 (2021)
Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dea567af161bdc07548c1280a7d542c
https://pure.eur.nl/en/publications/f4d5ebef-55fa-4986-a0fd-31a0368019df
https://pure.eur.nl/en/publications/f4d5ebef-55fa-4986-a0fd-31a0368019df
Autor:
Effie W Petersdorf, Mary Carrington, Colm O'hUigin, Mats Bengtsson, Dianne De Santis, Valerie Dubois, Ted Gooley, Mary Horowitz, Katharine Hsu, J Alejandro Madrigal, Martin J Maiers, Mari Malkki, Caroline McKallor, Yasuo Morishima, Machteld Oudshoorn, Stephen R Spellman, Jean Villard, Phil Stevenson, Martin Maiers, Stephen Spellman, Jane Apperley, Peter Bardy, Ghislaine Bernard, Yves Bertrand, Adrian Bloor, Chiara Bonini, Stephane Buhler, Laura Bungener, Helen Campbell, Kristina Carlson, Ben Carpenter, Anne Cesbron, Christian Chabannon, Yves Chalandon, Jeremy Chapman, Réda Chebel, Patrice Chevallier, Gerda Choi, Matt Collin, Jan J Cornelissen, Charles Crawley, Lloyd D'Orsogna, Jean-Hugues Dalle, Eric Deconinck, Muriel DeMatteis, Mary Diviney, Anne Dormoy, Katia Gagne, Brenda Gibson, Maria Gilleece, David Gottlieb, John Gribben, Tayfun Güngör, Mike Haagenson, Cathie Hart, Rhonda Holdsworth, Ian Humphreys, Yoshihisa Kodera, Mickey Koh, Hélène Labussière-Wallet, Arjan C Lankester, Neubery Lardy, Sarah Lawson, Xavier Leleu, Stephen MacKinnon, Ram Malladi, Steven GE Marsh, Murray Martin, Neema P Mayor, I Grant McQuaker, Ellen Meijer, Satoko Morishima, Emmanouil Nikolousis, Kim Orchard, Jacob Passweg, Amit Patel, Katherine Patrick, Béatrice Pedron, Andy Peniket, Julia Perry, Eefke Petersen, Victoria Potter, Mike Potter, Rachel Protheroe, Nicole Raus, Carmen Ruiz de Elvira, Nigel Russell, Nicholaas PM Schaap, Urs Schanz, Harry Schouten, Roderick Skinner, John Snowden, Eric Spierings, Colin Steward, Eleni Tholouli, Alycia Thornton, Marcel Tilanus, Arnold van de Meer, Hendrik Veelkens, Paul Veys, Narelle Watson, Lyanne Weston, Keith Wilson, Marie Wilson, Robert Wynn, József Zsiros
Publikováno v:
The Lancet Haematology
The Lancet Haematology, Elsevier, 2021, 7 (1), pp.e50-e60. ⟨10.1016/s2352-3026(19)30208-x⟩
Petersdorf, E W, Carrington, M, O'hUigin, C, Bengtsson, M, De Santis, D, Dubois, V, Gooley, T, Horowitz, M, Hsu, K, Madrigal, J A, Maiers, M J, Malkki, M, McKallor, C, Morishima, Y, Oudshoorn, M, Spellman, S R, Villard, J, Stevenson, P & International Histocompatibility Working Group in Hematopoietic Cell Transplantation 2020, ' Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation : a retrospective cohort study ', The Lancet Haematology, vol. 7, no. 1, pp. e50-e60 . https://doi.org/10.1016/S2352-3026(19)30208-X
The Lancet Haematology, 7(1), e50-e60. Lancet Publishing Group
The Lancet. Haematology, Vol. 7, No 1 (2020) pp. e50-e60
The Lancet Haematology, 7(1), E50-E60. ELSEVIER SCI LTD
The Lancet Haematology, 7(1), e50. Lancet Publishing Group
Lancet Haematol
The Lancet Haematology, Elsevier, 2021, 7 (1), pp.e50-e60. ⟨10.1016/s2352-3026(19)30208-x⟩
Petersdorf, E W, Carrington, M, O'hUigin, C, Bengtsson, M, De Santis, D, Dubois, V, Gooley, T, Horowitz, M, Hsu, K, Madrigal, J A, Maiers, M J, Malkki, M, McKallor, C, Morishima, Y, Oudshoorn, M, Spellman, S R, Villard, J, Stevenson, P & International Histocompatibility Working Group in Hematopoietic Cell Transplantation 2020, ' Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation : a retrospective cohort study ', The Lancet Haematology, vol. 7, no. 1, pp. e50-e60 . https://doi.org/10.1016/S2352-3026(19)30208-X
The Lancet Haematology, 7(1), e50-e60. Lancet Publishing Group
The Lancet. Haematology, Vol. 7, No 1 (2020) pp. e50-e60
The Lancet Haematology, 7(1), E50-E60. ELSEVIER SCI LTD
The Lancet Haematology, 7(1), e50. Lancet Publishing Group
Lancet Haematol
Background: The success of unrelated haemopoietic cell transplantation (HCT) is limited by graft-versus-host disease (GVHD), which is the main post-transplantation challenge when HLA-matched donors are unavailable. A sequence dimorphism in exon 1 of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::195a18e65915d7d3471d1ddf38d8b61a
https://www.hal.inserm.fr/inserm-03349714/document
https://www.hal.inserm.fr/inserm-03349714/document
Autor:
Arjan C. Lankester, Alice Bertaina, Andrew S. Moore, Birgitta Versluys, Jacek Wachowiak, Theodor Uden, Ian Nivison-Smith, Marc Ansari, Franco Locatelli, Kirsten Mischke, Martin Zimmermann, Henrik Hasle, Corinne Gerhardt, Jerry Stein, Leen Willems, Marc Bierings, Christina Peters, Martin Sauer, Jonas Abrahamsson, Dirk Reinhardt, Petr Sedlacek, Anna Pieczonka, Jean-Pierre Bourquin, Adriana Balduzzi
Publikováno v:
British journal of haematology, Vol. 189, No 4 (2020) pp. 745-750
Uden, T, Bertaina, A, Abrahamsson, J, Ansari, M, Balduzzi, A, Bourquin, J-P, Gerhardt, C, Bierings, M, Hasle, H, Lankester, A, Mischke, K, Moore, A S, Nivison-Smith, I, Pieczonka, A, Peters, C, Sedlacek, P, Reinhardt, D, Stein, J, Versluys, B, Wachowiak, J, Willems, L, Zimmermann, M, Locatelli, F & Sauer, M G 2020, ' Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia : a retrospective I-BFM analysis of 333 children ', British Journal of Haematology, vol. 189, no. 4, pp. 745-750 . https://doi.org/10.1111/bjh.16441
British Journal of Haematology. WILEY
British Journal of Haematology
Uden, T, Bertaina, A, Abrahamsson, J, Ansari, M, Balduzzi, A, Bourquin, J-P, Gerhardt, C, Bierings, M, Hasle, H, Lankester, A, Mischke, K, Moore, A S, Nivison-Smith, I, Pieczonka, A, Peters, C, Sedlacek, P, Reinhardt, D, Stein, J, Versluys, B, Wachowiak, J, Willems, L, Zimmermann, M, Locatelli, F & Sauer, M G 2020, ' Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia : a retrospective I-BFM analysis of 333 children ', British Journal of Haematology, vol. 189, no. 4, pp. 745-750 . https://doi.org/10.1111/bjh.16441
British Journal of Haematology. WILEY
British Journal of Haematology
Outcome of 333 children with acute myeloid leukaemia relapsing after a first allogeneic haematopoietic stem cell transplantation was analyzed. Four-year probability of overall survival (4y-pOS) was 14%. 4y-pOS for 122 children receiving a second haem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::857d4011eee946472e5bff2043cee0f4
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85078877303
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85078877303
Autor:
de la Fuente, Josu, Gluckman, Eliane, Makani, Julie, Telfer, Paul, Faulkner, Lawrence, Corbacioglu, Selim, Paediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation
Publikováno v:
The lancet. Haematology, Vol. 7, No 12 (2020) pp. e902-e911
Sickle cell disease is one of the most common, life-threatening, non-communicable diseases in the world and a major public health problem. Following the implementation of simple preventive and therapeutic modalities, infant mortality has almost been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1400::2560f167c6ade3eedf78b38156db10e4
https://archive-ouverte.unige.ch/unige:156647
https://archive-ouverte.unige.ch/unige:156647
BACKGROUND: The success of unrelated haemopoietic cell transplantation (HCT) is limited by graft-versus-host disease (GVHD), which is the main post-transplantation challenge when HLA-matched donors are unavailable. A sequence dimorphism in exon 1 of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10691::aa240f117740cec8167386f40e0fcc44
https://dspace.library.uu.nl/handle/1874/394023
https://dspace.library.uu.nl/handle/1874/394023
Autor:
Henrique Bittencourt, Tiago Nava, M A Rezgui, Chakradhara Rao S. Uppugunduri, Marc Ansari, Michel Duval, Maja Krajinovic, Patricia Huezo-Diaz Curtis, Yves Théorêt, Liane Esteves Daudt
Publikováno v:
Biology of Blood and Marrow Transplantation, Vol. 23, No 11 (2017) pp. 1918-1924
Busulfan (Bu) is a key component of conditioning regimens used before hematopoietic stem cell transplantation (SCT) in children. Different predictive methods have been used to calculate the first dose of Bu. To evaluate the necessity of further impro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a655fdc25d856cee584a41d87dab7ba6
https://doi.org/10.1016/j.bbmt.2017.07.022
https://doi.org/10.1016/j.bbmt.2017.07.022
Autor:
John A. Snowden, Chris Hawkey, Daniel Hind, Lizzie Swaby, Katie Mellor, Richard Emsley, Laura Mandefield, Ellen Lee, Manuela Badoglio, Emmanuelle Polge, Myriam Labopin, John Gribben, A. Graham Pockley, Gemma A. Foulds, Alan Lobo, Simon Travis, Miles Parkes, Jack Satsangi, Diana Papaioannou, James O. Lindsay, on Behalf of the Autologous Stem Cell Transplantation In Refractory CD - Low Intensity Therapy Evaluation Study Investigators, the European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP)
Publikováno v:
BMC Gastroenterology, Vol 19, Iss 1, Pp 1-14 (2019)
BMC Gastroenterology
2019, ' Autologous stem cell transplantation in refractory Crohn's disease-low intensity therapy evaluation (ASTIClite) : study protocols for a multicentre, randomised controlled trial and observational follow up study ', BMC GASTROENTEROLOGY, vol. 19, no. 1, 82, pp. 82 . https://doi.org/10.1186/s12876-019-0992-2
Snowden, J A, Hawkey, C, Hind, D, Swaby, L, Mellor, K, Emsley, R, Mandefield, L, Lee, E, Badoglio, M, Polge, E, Labopin, M, Gribben, J, Pockley, A G, Foulds, G A, Lobo, A, Travis, S, Parkes, M, Satsangi, J & Papaioannou, D & Lindsay, J O 2019, ' Autologous stem cell transplantation in refractory Crohn's disease-low intensity therapy evaluation (ASTIClite) : study protocols for a multicentre, randomised controlled trial and observational follow up study ', BMC gastroenterology, vol. 19, no. 1, pp. 82 . https://doi.org/10.1186/s12876-019-0992-2
BMC Gastroenterology
2019, ' Autologous stem cell transplantation in refractory Crohn's disease-low intensity therapy evaluation (ASTIClite) : study protocols for a multicentre, randomised controlled trial and observational follow up study ', BMC GASTROENTEROLOGY, vol. 19, no. 1, 82, pp. 82 . https://doi.org/10.1186/s12876-019-0992-2
Snowden, J A, Hawkey, C, Hind, D, Swaby, L, Mellor, K, Emsley, R, Mandefield, L, Lee, E, Badoglio, M, Polge, E, Labopin, M, Gribben, J, Pockley, A G, Foulds, G A, Lobo, A, Travis, S, Parkes, M, Satsangi, J & Papaioannou, D & Lindsay, J O 2019, ' Autologous stem cell transplantation in refractory Crohn's disease-low intensity therapy evaluation (ASTIClite) : study protocols for a multicentre, randomised controlled trial and observational follow up study ', BMC gastroenterology, vol. 19, no. 1, pp. 82 . https://doi.org/10.1186/s12876-019-0992-2
Background\ud \ud Intestinal inflammation in Crohn’s disease (CD) is caused by mucosal immune system reactivity to luminal antigen and results in debilitating symptoms, reduced quality of life, impaired work productivity and significant health care
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::428edd83ed68c29b2122e9a146ecd5bb
Autor:
Myriam Labopin, Ibrahim Yakoub-Agha, Nicolaus Kröger, Jiří Pavlů, Gérard Socié, Sebastian Giebel, Dietrich W. Beelen, Arnon Nagler, Mahmoud Aljurf, Zinaida Peric, Hélène Labussière-Wallet, Jakob Passweg, Riitta Niittyvuopio, Mohamad Mohty, Péter Reményi, Depei Wu
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 12, Iss 1, Pp 1-9 (2019)
Journal of Hematology & Oncology, Vol 12, Iss 1, Pp 1-9 (2019)
Background Assessment of measurable residual disease (MRD) is rapidly transforming the therapeutic and prognostic landscape of a wide range of hematological malignancies. Its prognostic value in acute lymphoblastic leukemia (ALL) has been established
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76e06ad1ef9327a72308cc6c3b50da37
https://doi.org/10.1186/s13045-019-0790-x
https://doi.org/10.1186/s13045-019-0790-x